• Explore /
  • Poster
  • / CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.

CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.

Abstract Poster

Authors

null

Chia Jui Yen

Department of Oncology, National Cheng Kung University Hospital, Tainan, Taiwan

Chia Jui Yen , Yi-Hsiang Huang , Kun-Yun Yeh , Pei-Jer Chen , Sheng-Nan Lu , John Gutheil , Teresa J. Melink , Yen-Ling Chen , Chun-Man Chen , Ting-Yu (Tiffany) Chao , Yi-Wen Chu , Du-Shieng Chien

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies

Sub Track

Targeted Therapies

Clinical Trial Registration Number

NCT05257590

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 92)

DOI

10.1200/JCO.2024.42.23_suppl.92

Abstract #

92

Poster Bd #

G4

Abstract Disclosures

Similar Posters

First Author: Richard S. Finn

First Author: Stephen Chan

First Author: Lorenza Rimassa

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study.

Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study.

First Author: Yoshinari Asaoka